Mitsubishi Tanabe taps Synageva for orphan drug R&D
This article was originally published in Scrip
Executive Summary
The US orphan drug firm Synageva BioPharma is to carry out research into a novel therapeutic molecule for an undisclosed but "devastating" orphan disease in a new collaboration with Mitsubishi Tanabe Pharma (MTP).